A pilot study of serum anti-Mullerian hormone in diagnosis of polycystic ovary syndrome based on 2012 Chinese polycystic ovary syndrome diagnosis criteria

Abstract

Based on 2012 Chinese polycystic ovary syndrome (PCOS) diagnosis criteria, we detect the serum anti-Müllerian hormone (AMH) levels in PCOS patients, to evaluate the diagnosis value of AMH for PCOS. Totally 217 PCOS patients were chosen as study group and 204 non-PCOS women were as controls. Their clinical information (body weight, score for acne and hirsutism), ultrasonography for ovarian volume and the number of small follicle, and blood sample detected for hormonal and metabolic parameters were obtained. Spearman's analysis and the receiver operating characteristic curve (ROC curve) were used to assess relevance and the diagnostic efficiency of AMH in PCOS. Serum AMH level was significantly higher in PCOS group compared with the control group (105.46 versus 26.28 pmol/L, P<0.01). Serum AMH were positively related to Ferriman and Gallwey (F-G) score (r=0.526, P<0.01), global acne grading system (GAGS) score (r=0.359, P<0.01), total testosterone (r=0.514, P<0.01), LH/FSH ratio (r=0.542, P<0.01), fasting plasma glucose (r=0.373, P<0.01), fasting insulin (r=0.168, P=0.008), homeostasis model assessment for insulin resistance (HOMA-IR) index (r=0.182, P=0.004), total cholesterol (r=0.247, P<0.01), triglyceride (r=0.235, P<0.01), total ovarian volume (r=0.204, P=0.008), and mean number of small follicle (r=0.693, P<0.01). The area under the ROC curve for PCOS diagnosed by AMH was 0.954 (P<0.01). the threshold of AMH for PCOS diagnosis was 57.76 pmol/L, diagnostic efficiency was high (sensitivity 95.1%, specificity 89.3%). Based on 2012 Chinese PCOS diagnosis criteria, serum AMH level elevated in PCOS, and correlated with women's hormonal imbalance and abnormal follicular development.